Preliminary Results of Paclitaxel, Cisplatin and Concurrent High-Dose Radiation Therapy for Locally Advanced Non-Small-Cell Lung Cancer

Cancer Research and Treatment 2002³â 34±Ç 5È£ p.345 ~ p.351

ÀÌ»ó¿í(Lee Sang-Wook) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
ÃÖÀº°æ(Choi Eun-Kyung) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
¿À¼®Áß(Oh Suk-Joong) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
(Suh Cheol-Won) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
±è»óÀ§(Kim Sang-We) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
ÀÌÁ¤½Å(Lee Jung-Shin) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
±èµ¿¼ø(Kim Dong-Soon) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
±è¿øµ¿(Kim Won-Dong) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
±è¿ì¼º(Kim Woo-Seong) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
ÀÌ»óµµ(Lee Sang-Do) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
±èÁ¾ÈÆ(Kim Jong-Hoon) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
¾È½Âµµ(Ahn Seung-Do) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
±è°æÁÖ(Kim Kyoung-Ju) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology
³ë¿µÁÖ(Noh Young-Ju) - University of Ulsan College of Medicine Asan Medical Center Department of Radiation Oncology

Abstract

Å°¿öµå

Non-small cell lung cancer, Concurrent chemoradiation, Conformal radiotherapy,
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
SCI(E) MEDLINE ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
This combined modality has activity with manageable toxicity and 23 months in mean survival time
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå